EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma

Julia Schiantarelli, Mouadh Benamar, Jihye Park, Haley E Sax, Giacomo Oliveira, Alice Bosma-Moody, Katie M Campbell, David Liu, Douglas B Johnson, Scott Rodig, Catherine J Wu, F Stephen Hodi und 3 weitere

Cancer Cell · 2025-02 · 43 (2) · 308-316.e6

DOI: 10.1016/j.ccell.2025.01.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2025-02. Verfasst von Julia Schiantarelli und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Camb…. Hauptthemen laut MEDLINE: Melanoma, Drug Resistance, Neoplasm, Immune Checkpoint Inhibitors, Immunotherapy. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, The Mark Foundation for Cancer Research, Novartis Institutes for BioMedical Research Basel.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although some patients with metastatic melanoma experience durable responses to immune checkpoint inhibitors (ICIs), most exhibit intrinsic or acquired resistance to these therapies. Here, we compare somatic genomic profiles from matched pre-treatment and post-resistance tumor biopsies in patients (n = 25) with metastatic melanoma who exhibited heterogeneous ICI responses to nominate additional mediators of acquired resistance. We find that several acquired resistance tumors exhibit defects in B2M or JAK1/2, consistent with prior findings. We also discover resistance-associated mutations in SEC24C and SEC24D in 3 patients. SEC24 has an essential role in the trafficking of the dsDNA sensor STING and has been linked to interferonopathies. Melanoma cells engineered to express the SEC24C mutations observed in patients exhibit diminished STING signaling, including decreased type I interferon production, antigen presentation, and a reduced capacity to activate cytotoxic T cells. This study nominates a role for aberrant STING trafficking in acquired resistance to ICIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaDrug Resistance, NeoplasmImmune Checkpoint InhibitorsImmunotherapyHumansMutationMembrane ProteinsCell Line, TumorSTING Protein

Stichwörter der Autor:innen

SEC24STING signalingacquired resistanceimmune checkpoint inhibitorsmetastatic melanoma

Substanzen

Immune Checkpoint InhibitorsMembrane ProteinsSTING1 protein, humanSTING Protein

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
  • Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Parker Institute for Cancer Immunotherapy, Dana-…

Förderung

  • NCI NIH HHS
  • The Mark Foundation for Cancer Research
  • Novartis Institutes for BioMedical Research Basel
  • Doris Duke Charitable Foundation
  • Melanoma Research Alliance
  • National Institutes of Health
  • Parker Institute for Cancer Immunotherapy

Zitieren

APA

Schiantarelli, J., Benamar, M., Park, J., Sax, H. E., Oliveira, G., Bosma-Moody, A., Campbell, K. M., Liu, D., Johnson, D. B., Rodig, S., Wu, C. J., Hodi, F. S., Ribas, A., Van Allen, E., & Haq, R. (2025). Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma. Cancer Cell, 43(2), 308-316.e6. https://doi.org/10.1016/j.ccell.2025.01.009

Vancouver

Schiantarelli J, Benamar M, Park J, Sax HE, Oliveira G, Bosma-Moody A, et al. Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma. Cancer Cell. 2025;43(2):308-316.e6. doi:10.1016/j.ccell.2025.01.009

BibTeX
@article{Schiantarelli2025,
  author = {Schiantarelli, Julia and Benamar, Mouadh and Park, Jihye and Sax, Haley E and Oliveira, Giacomo and Bosma-Moody, Alice and Campbell, Katie M and Liu, David and Johnson, Douglas B and Rodig, Scott and Wu, Catherine J and Hodi, F Stephen and Ribas, Antoni and Van Allen, Eliezer and Haq, Rizwan},
  title = {Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma},
  journal = {Cancer Cell},
  year = {2025},
  volume = {43},
  number = {2},
  pages = {308--316.e6},
  doi = {10.1016/j.ccell.2025.01.009}
}
Kostenlos starten →